Archive for October, 2011:

Stage I research of temsirolimus in combination with EKB-569 in individuals with state-of-the-art sound tumors.

Stage I research of temsirolimus in combination with EKB-569 in individuals with state-of-the-art sound tumors. Source Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85255, USA, bryce.alan@mayo.edu. Abstract Objective Activation of EGFR can promote proliferative and survival signaling through mTOR. Preclinical data demonstrates synergistic action of combined EGFR and mTOR inhibition. We undertook a phase

(Read More…)

The threonine kinases that handle cell cycle progression as therapeutic targets.

The serine/threonine kinases that handle cell cycle progression as therapeutic targets. Diallo A, Prigent C. Abstract Cell cycle progression corresponds to a sequence of events, which be successful one another to finish within the division of the mom cell to offer two daughter cells. The processes that allow the cell to divide are extremely precisely

(Read More…)

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O’Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. “J Clin Oncol. 2011 Jun” PURPOSE: Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase

(Read More…)

© Apoptosis|apoptosis inhibitor|apoptosis pathway
CyberChimps